Sanara MedTech develops and markets surgical and wound care products including CellerateRX Surgical collagen for wound management, BIASURGE surgical irrigation solutions and FORTIFY tissue repair grafts. The company also offers bone graft substitutes, amniotic membrane allografts and antimicrobial wound products. These are sold to hospitals, clinics and post-acute providers to support better surgical and healing outcomes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 23.4 | — | -3.5 | — |
| Q2 2025 | 25.8 | — | -2 | — |
| Q3 2025 | 26.3 | — | -30.4 | — |
| Q4 2025 | 27.6 | — | -1.6 | — |
| Q1 2026 | 27.8 | 18.6% | 0.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Anbio Biotechnology (NNNN), Andretti Acquisition Corp. II (POLE), Range Capital Acquisition Corp II (RNGT), Jack in the Box Inc. (JACK), Repay Holdings Corporation (RPAY), Texas Ventures Acquisition III Corp (TVA)